Prior to the approval of Nymalize, nimodipine was available only in gel capsule form...Sorrento Therapeutics Inc., of San Diego, and Igdrasol Inc., of Irvine, Calif., said they acquired exclusive distribution rights from Samyang Biopharmaceuticals, a South Korean firm, to Cynviloq (marketed as Genexol-PM in South Korea) in the 27 countries of the European Union

Even after the news broke Monday – and the Theravance share price (NASDAQ:THRX) gained more than 14 percent to hit $40 – the entire company was still only valued at $3.94 billion...Editor's note: To obtain a CD of the webinar, "Royalty Financing for Biotech and Medical Device Companies: How to Determine Eligibility and Take Advantage of this Unique Financing Opportunity" or for a deeper dive, BioWorld's Biopharmaceutical Royalty Rates Analysis: Essential Benchmarks for Dealmaking, call 800-477-6307

ProQinase GmbH, of Freiburg, Germany, and Mercachem BV, of Nijmegen, the Netherlands, received a €2.5 million (US$3.24 million) grant from the European Union's Eurostars program to support their joint efforts to establish and expand a small molecule drug discovery platform that will combine biological and pharmacological assay systems with chemical space libraries targeted against most prominent epigenetic enzyme families...Kinnovata plans to develop, manufacture and commercialize respiratory

Even after the news broke Monday – and the Theravance share price (NASDAQ:THRX) gained more than 14 percent to hit $40 – the entire company was still only valued at $3.94 billion...Editor's note: To obtain a CD of the webinar, "Royalty Financing for Biotech and Medical Device Companies: How to Determine Eligibility and Take Advantage of this Unique Financing Opportunity" or for a deeper dive, BioWorld's Biopharmaceutical Royalty Rates Analysis: Essential Benchmarks for Dealmaking, call 800-477-6307

turned its attention to other candidates in its pipeline...continue to view shares as undervalued based on the >$1B potential of ISIS-SMN-Rx, as well as the promise of ISIS-TTR-Rx and Isis' 20+ other pipeline candidates," he wrote...In other earnings news

Allergan licensed rights to the Darpin technology from Molecular Partners AG for development in AMD and other eye diseases. (See BioWorld Today, Aug. 22, 2012.) And Eylea has fared well so far against Roche AG's Lucentis (ranibizumab), due to its lower cost and a label that calls for less frequent dosing, and even to cancer drug Avastin (bevacizumab), a cheaper, off-label alternative

In separate news, another Galapagos unit, Argenta, inked a deal with Boehringer Ingelheim GmbH, of Ingelheim, Germany, to apply its respiratory drug discovery services to an undisclosed target within Boehringer's respiratory disease portfolio...In other news, BioInvent said the first patient has been treated in a Phase II study of BI-505 for smoldering multiple myeloma, or asymptomatic myeloma

Celltrion said it plans to submit the study application in the first half of this year, he added, which could allow for the trial to start in the second of this year...To date, Celltrion and Hospira have identified only two products from the alliance – Remsima, a biosimilar version of autoimmune drug Remicade (infliximab, Johnson & Johnson), which won approval as the first biosimilar monoclonal antibody last year in Korea, and a biosimilar version of breast cancer drug Herceptin (trastuzumab, Roche

to begin a Phase IIa trial of BL-8040, a selective antagonist of chemokine receptor CXCR4, in acute myeloid leukemia (AML...According to the terms, Shasun will be able to use the Debiopharm technology to manufacture synthetic Huperzine-A under GMP quality conditions and commercialize it in pharmaceutical and nutraceutical markets...In other news, GSK experienced manufacturing delays for manufacture and supply of Horizant (gabapentin enacarbil), partnered with XenoPort Inc., of Santa Clara, Calif

Targeting 25% of $20B Market Tecarfarin (ATI-5923) recently completed a Phase III study demonstrating safety and effectiveness in patients with prosthetic heart valves in addition to those with other conditions such as atrial fibrillation or venous thromboembolism, independent of CYP status...Kengatharan declined to disclose Armetheon's financing to date but said the company is able to draw from a convertible note as it moves toward a Series A...Armetheon is meeting with investment bankers to complete

In the most recent action in the case, the mass torts law firm of Watts Guerra LLP, of San Antonio, has filed a motion to consolidate the incretins litigation nationally...Pradax is used to prevent clotting in patients who suffer from atrial fibrillation...Sanofi Pasteur Ltd., of Lyon, France, the vaccines division of Sanofi SA, said a decentralized marketing authorization application has been accepted for review in the European Union (EU) countries for a quadrivalent formulation of Vaxigrip, Sanofi

The company expects to see results from by late summer...Gilead said it will file for regulatory approval of sofosbuvir in other territories during the second quarter, including the European Union, where the European Medicines Agency accepted the company's request for accelerated assessment

The company plans to submit an application for registration in the European Union by the end of April...The company's technology fuses candidate vaccine antigens from malaria to self-assembling proteins from the ciliated protozoan, Tetrahymena, to create nanometer-sized particles called G-Somes that have the potential to be highly immunogenic in humans and other vertebrate hosts

In separate news, Astellas signed a deal to access the TSUBAME2.0 supercomputer at the Tokyo Institute of Technology to discover candidates for NTDs caused by dengue virus...In other news, The Nasdaq OMX Stockholm's listing committee approved the listing of NeuroVive's shares

Sosei licensed Japanese rights to the compound from BioAlliance, which markets the product as Loramyc/Oravig...The studies are designed to allow PCT to evaluate the applicability of SistemQC technology in stem cell characterization employing Sistemic's miRNA profiling system and analytical approaches to product miRNA panels

ThromboGenics NV is banking a €45 million (US$58.8 million) milestone payment from its partner, Alcon, a unit of Novartis AG, following formal European Union (EU) approval for Jetrea (ocriplasmin) for treating patients with vitreomacular traction (VMT), including those with a macular hole up to 400 microns in diameter...The news was hardly unexpected, as the product was nodded through by the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) in January...Those and other

The parties agreed to a settlement payment of $40 million, $38 million of which will be funded by Dendreon's insurers...sales and distribution rights to Abstral (fentanyl) sublingual tablets from Orexo AB, of Uppsala, Sweden...An independent assessment to confirm the diagnosis and evaluate the cause is planned

ThromboGenics NV is banking a €45 million (US$58.8 million) milestone payment from its partner, Alcon, a unit of Novartis AG, following formal European Union (EU) approval for Jetrea (ocriplasmin) for treating patients with vitreomacular traction (VMT), including those with a macular hole up to 400 microns in diameter...The news was hardly unexpected, as the product was nodded through by the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) in January...Those and other

Clinigen Group plc, of Burton-on-Trent, UK, and Theravance Inc., of South San Francisco, entered an exclusive commercialization agreement in the European Union and certain other countries located in Europe for Vibativ (telavancin) in nosocomial pneumonia, including ventilator-associated pneumonia, known or suspected to be caused by methicillin-resistant Staphylococcus aureus, when other alternatives are not suitable...In other news, Elan said its Tysabri (natalizumab) restructuring transaction is